CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
Open Access
- 15 July 2016
- journal article
- case report
- Published by Wiley in Annals of Neurology
- Vol. 80 (2) , 294-300
Abstract
We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4‐blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T‐cell type MS. Quantitative next generation sequencing of T‐cell receptor genes revealed distinct oligoclonal CD4+ and CD8+ T‐cell repertoires in the primary melanoma and cerebrospinal fluid. Our results pinpoint the coinhibitory molecule CTLA4 as an immunological checkpoint and therapeutic target in MS. Ann Neurol 2016;80:294–300Keywords
This publication has 26 references indexed in Scilit:
- Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluidNature, 2016
- Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunityJournal of Experimental Medicine, 2015
- Immunopathology of multiple sclerosisNature Reviews Immunology, 2015
- The future of immune checkpoint therapyScience, 2015
- Multiple sclerosis geneticsThe Lancet Neurology, 2014
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- The genetics of multiple sclerosis: an up‐to‐date reviewImmunological Reviews, 2012
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelinationAnnals of Neurology, 2000
- CTLA-4: a negative regulator of autoimmune disease.Journal of Experimental Medicine, 1996